Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group

被引：6

作者：

del Alcazar, Elena ^{[1
]}

Lopez-Ferrer, Anna ^{[2
]}

Martinez-Domenech, Alvaro ^{[3
]}

Julia, Marc ^{[4
]}

Ruiz-Villaverde, Ricardo ^{[5
]}

Rodriguez Fernandez-Freire, Lourdes ^{[6
]}

Notario, Jaime ^{[7
]}

Llamas-Velasco, Mar ^{[8
]}

Ferran, Marta ^{[9
]}

Carrascosa, Jose Manuel ^{[10
]}

机构：

[1] Univ Autonoma Barcelona UAB, Dept Dermatol, Hosp Univ Germans Trias & Pujol, Badalona, Spain

[2] Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain

[3] Hosp Gen Univ Valencia, Dept Dermatol, Valencia, Spain

[4] Hosp Univ Basurto, Dept Dermatol, Bilbao, Spain

[5] Hosp Clin Univ San Cecilio, Dept Dermatol, Granada, Spain

[6] Hosp Univ Virgen Rocio, Dept Dermatol, Seville, Spain

[7] Univ Bellvitge, Dept Dermatol, Barcelona, Spain

[8] Hosp Univ Princesa, Dept Dermatol, Madrid, Spain

[9] Hosp Mar Inst Mar Invest Med, Dept Dermatol, Barcelona, Spain

[10] Univ Autonoma Barcelona UAB, Hosp Univ Germans Trias & Pujol, Dept Dermatol, Badalona, Spain

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2022年 / 33卷 / 06期

关键词：

D O I：

10.1080/09546634.2022.2079596

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：2878 / 2880

页数：3

共 10 条

[1] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].

Blauvelt, Andrew ;

Papp, Kim A. ;

Griffiths, Christopher E. M. ;

Randazzo, Bruce ;

Wasfi, Yasmine ;

Shen, Yaung-Kaung ;

Li, Shu ;

Kimball, Alexa B. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417

[2] Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study [J].

Dapavo, Paolo ;

Siliquini, Niccolo ;

Mastorino, Luca ;

Avallone, Gianluca ;

Merli, Martina ;

Agostini, Andrea ;

Cariti, Caterina ;

Viola, Riccardo ;

Stroppiana, Elena ;

Verrone, Anna ;

Ortoncelli, Michela ;

Quaglino, Pietro ;

Ribero, Simone .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) :2352-2357

[3] Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group [J].

del Alcazar, Elena ;

Lopez-Ferrer, Anna ;

Martinez-Domenech, Alvaro ;

Ruiz-Villaverde, Ricardo ;

Llamas-Velasco, Ma. del Mar ;

Rocamora, Vicenc ;

Julia, Marc ;

Notario, Jaime ;

Fernandez-Freire, Lourdes Rodriguez ;

Sahuquillo-Torralba, Antonio ;

Vidal, David ;

Rivera, Raquel ;

Carretero, Gregorio ;

Mateu, Almudena ;

de la Cueva, Pablo ;

Carrascosa, Jose Manuel .

DERMATOLOGIC THERAPY, 2022, 35 (02)

[4] Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis [J].

Iznardo, H. ;

Vilarrasa, E. ;

Lopez-Ferrer, A. ;

Puig, L. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) :660-662

[5] Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study [J].

Lytvyn, Yuliya ;

Zaaroura, Hiba ;

Mufti, Asfandyar ;

Alabdulrazzaq, Shaikhah ;

Yeung, Jensen .

JAAD INTERNATIONAL, 2021, 4 :49-51

[6] Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis [J].

Malkonen, Tarja ;

Nuutinen, Pauliina ;

Hallinen, Taru ;

Soini, Erkki ;

Nissinen, Riikka ;

Wennerstom, Christina ;

Rantanen, Tapio ;

Hagman, Johanna H. ;

Harvima, Rauno ;

Hook-Nikanne, Johanna ;

Ilves, Tiina ;

Lintu, Paivi ;

Malanin, Ken ;

Soramaki, Iina ;

Tasanen, Kaisa ;

Teho, Arja ;

Vahavihu, Katja ;

Italinna, Sari ;

Leinonen, Pekka ;

Sarajarvi, Piia ;

Huilaja, Laura ;

Pasternack, Rafael .

ACTA DERMATO-VENEREOLOGICA, 2022, 102

[7] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial [J].

Reich, Kristian ;

Armstrong, April W. ;

Foley, Peter ;

Song, Michael ;

Wasfi, Yasmine ;

Randazzo, Bruce ;

Li, Shu ;

Shen, Y. -K. ;

Gordon, Kenneth B. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :418-431

[8] Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice [J].

Ruiz-Villaverde, Ricardo ;

Rodriguez-Fernandez-Freire, Lourdes ;

Armario-Hita, Jose Carlos ;

Perez-Gil, Amalia ;

Galan-Gutierrez, Manuel .

DERMATOLOGIC THERAPY, 2021, 34 (02)

[9] Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study [J].

Schwensen, J. F. B. ;

Nielsen, V. W. ;

Nissen, C. V. ;

Sand, C. ;

Gniadecki, R. ;

Thomsen, S. F. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (05) :E341-E343

[10] Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study [J].

Torres, Tiago ;

Puig, Luis ;

Vender, Ron ;

Lynde, Charles ;

Piaserico, Stefano ;

Carrascosa, Jose M. ;

Gisondi, Paolo ;

Dauden, Esteban ;

Conrad, Curdin ;

Mendes-Bastos, Pedro ;

Ferreira, Paulo ;

Leite, Luiz ;

Lu, Justin D. ;

Valerio, J. ;

Bruni, M. ;

Messina, F. ;

Nidegger, A. ;

Llamas-Velasco, M. ;

del Alcazar, E. ;

Mufti, A. ;

White, Kyra ;

Caldarola, G. ;

Teixeira, Laetitia ;

Romanelli, Paolo ;

Desai, K. ;

Gkalpakiotis, Spyridon ;

Romanelli, Marco ;

Yeung, Jensen ;

Nogueira, Miguel ;

Chiricozzi, Andrea .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (04) :567-579

← 1 →